Jane J. Kim: Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States. In: Annals of Internal Medicine. 151. Jahrgang, Nr.8, 19. Oktober 2009, S.538–545 (annals.org [abgerufen am 20. Oktober 2009]).
O Damm, M Nocon, S Roll, C Vauth, SN Willich, W Greiner: Impfung gegen humane Papillomaviren (HPV) zur Prävention HPV 16/18 induzierter Zervixkarzinome und derer Vorstufen. Schriftenreihe Health Technology Assessment, 2009, Band 83, 1. Auflage dimdi.de (PDF; 689 kB) abgerufen am 11. März 2009
Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleton, Dorothy J Wiley, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark H Stoler, Jack Cuzick, Suzanne M Garland, Susanne K Kjaer, Oliver M Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C Roberts, Christine Shields, Alain Luxembourg: Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind Trial. Lancet 390 (2017), S. 2143–2159, PMID 28886907, doi:10.1016/S0140-6736(17)31821-4
Julio Cesar González-Rodríguez et al.: Cervical cancer prevention by vaccination: review. In: Frontiers in Oncology. Band14, 2024, S.1386167, doi:10.3389/fonc.2024.1386167, PMID 38715779 (englisch).
Julia ML Brotherton, Masha Fridman, Cathryn L May, Genevieve Chappell, A Marion Saville, Dorota M Gertig: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. In: Lancet, 377, 2011, S. 2085–2092, doi:10.1016/S0140-6736(11)60551-5
Marc Arbyn et al.: Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. In: Cochrane Database of Systematic Reviews. Band2020, Nr.3, 9. Mai 2018, doi:10.1002/14651858.CD009069.pub3, PMID 29740819, PMC 6494566 (freier Volltext) – (englisch).
Tim Palmer et al.: Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. In: BMJ. Band365, 3. April 2019, S.l1161, doi:10.1136/bmj.l1161, PMID 30944092 (englisch).
Mélanie Drolet et al.: Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. In: Lancet (London, England). Band394, Nr.10197, 10. August 2019, S.497–509, doi:10.1016/S0140-6736(19)30298-3, PMID 31255301.
Nancy M. McClung et al.: Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey. In: Journal of Adolescent Health. Band65, Nr.6, 1. Dezember 2019, S.715–722, doi:10.1016/j.jadohealth.2019.07.003.
Jiayao Lei et al.: HPV Vaccination and the Risk of Invasive Cervical Cancer. In: The New England Journal of Medicine. Band383, Nr.14, 1. Oktober 2020, S.1340–1348, doi:10.1056/NEJMoa1917338, PMID 32997908 (englisch).
Milena Falcaro et al.: The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. In: The Lancet. 3. November 2021, doi:10.1016/S0140-6736(21)02178-4, PMID 34741816 (englisch).
Susanne K. Kjaer et al.: Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. In: Journal of the National Cancer Institute. Band113, Nr.10, 1. Oktober 2021, S.1329–1335, doi:10.1093/jnci/djab080, PMID 33876216, PMC 8486335 (freier Volltext) – (englisch).
Tim J. Palmer et al.: Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. In: Journal of the National Cancer Institute. 22. Januar 2024, S.djad263, doi:10.1093/jnci/djad263, PMID 38247547 (englisch).
Marc Arbyn et al.: Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer. In: Journal of the National Cancer Institute. 19. März 2024, S.djae042, doi:10.1093/jnci/djae042, PMID 38501990 (englisch).
Anna R. Giuliano et al.: Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. In: New England Journal of Medicine. Band364, Nr.5, 3. Februar 2011, S.401–411, doi:10.1056/NEJMoa0909537, PMID 21288094, PMC 3495065 (freier Volltext).
H M Hepburn, A M Kaufmann: Nobelpreis für die Impfung gegen Zervixkrebs. Aktuelle Daten- und Leitlinienlage. In: Internist, 50, 2009, S. 617–626, doi:10.1007/s00108-009-2388-9
Paavonen J et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. In: The Lancet. 369. Jahrgang, Nr.9580, Juni 2007, S.2161–70, doi:10.1016/S0140-6736(07)60946-5, PMID 17602732.
Yvonne Deleré et al.: Effektivität und Dauer des Impfschutzes gegen humane Papillomviren: Systematische Literaturübersicht und Metaanalyse. In: Dtsch Arztebl Int, 111, 2014, S. 584–591, doi:10.3238/arztebl.2014.0584
A R Kreimer et al.: Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. In: The Lancet, online veröffentlicht am 10. Juni 2015 doi:10.1016/S1470-2045(15)70199-3
Yutaka Ueda et al.: The last strategy for re-dissemination of HPV vaccination in Japan while still under the suspension of the governmental recommendation. In: Scientific Reports. Band10, Nr.1, 30. September 2020, S.16091, doi:10.1038/s41598-020-73120-1.
Keiko Kunitoki et al.: Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence. In: Vaccine. Band39, Nr.41, 1. Oktober 2021, S.6104–6110, doi:10.1016/j.vaccine.2021.08.085.
Satoshi Iwata, Kenji Okada, Kei Kawana: Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine. Vaccine 35 (2017), S. 2291–2292, PMID 28325478, doi:10.1016/j.vaccine.2017.03.015, vaccine-kyogikai.umin.jp (PDF; 219 kB)
Francisco A. R. Garcia, Debbie Saslow: Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention. In: Obstetrics and Gynecology Clinics of North America. Band34, Nr.4, Dezember 2007, S.761–781, ix, doi:10.1016/j.ogc.2007.09.007, PMID 18061868.
Nikolai Madrid Scheller, Björn Pasternak, Henrik Svanström, Anders Hviid: Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. In: JAMA. Band312, Nr.2, Juli 2014, S.187–188, doi:10.1001/jama.2014.2198, PMID 25005658.
Nikolai Madrid Scheller, Henrik Svanström, Björn Pasternak, Lisen Arnheim-Dahlström, Karin Sundström, Katharina Fink, Anders Hviid: Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System In: JAMA, 313, 2015, S. 54–61, doi:10.1001/jama.2014.16946.
David Hawkes: Evidence evolves over time and should be based on data not opinion. In: BMJ Evidence-Based Medicine. Band25, Nr.6, 1. Dezember 2020, S.191–192, doi:10.1136/bmjebm-2019-111222, PMID 31548208.
Marco Torella et al.: Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence. In: Vaccines. Band11, Nr.1, 9. Januar 2023, S.140, doi:10.3390/vaccines11010140, PMID 36679985, PMC 9866915 (freier Volltext) – (englisch).
L Jørgensen, PC Gøtzsche, T. Jefferson: The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. BMJ Evidence-Based Medicine 2018; 23, S. 165–168, doi:10.1136/bmjebm-2018-111012
Ilkka Kalliala et al.: Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial. In: Preventive Medicine. Band146, Mai 2021, S.106473, doi:10.1016/j.ypmed.2021.106473, PMID 33639181 (englisch).
Pola Olczak, Richard B. S. Roden: Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases. In: Vaccines. Band8, Nr.4, 1. Oktober 2020, S.568, doi:10.3390/vaccines8040568, PMID 33019516, PMC 7712070 (freier Volltext) – (englisch).
Christina Schellenbacher et al.: HPV-Impfstoffe – zugelassene Vakzinen und experimenteller RG1-VLP-Impfstoff der nächsten Generation. In: hautnah. Band20, Nr.3, 1. September 2021, S.155–160, doi:10.1007/s12326-021-00453-7.
Emily Farmer et al.: Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer. In: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. Band217, 2021, S.157–195, doi:10.1007/978-3-030-57362-1_8, PMID 33200366, PMC 8564785 (freier Volltext).
Sebastian Kruse et al.: Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. In: OncoImmunology. Band8, Nr.1, 2. Januar 2019, S.e1524694, doi:10.1080/2162402X.2018.1524694, PMID 30546964, PMC 6287800 (freier Volltext).
Stefanie J. Klug, Meike Hukelmann, Bettina Hollwitz, Nurgül Düzenli, Betti Schopp, Karl-Ulrich Petry, Thomas Iftner: Prevalence of human papillomavirus types in women screened by cytology in Germany. In: J Med Virol 79 (2007), S. 616–25, PMID 17385693.
Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleton, Dorothy J Wiley, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark H Stoler, Jack Cuzick, Suzanne M Garland, Susanne K Kjaer, Oliver M Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C Roberts, Christine Shields, Alain Luxembourg: Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind Trial. Lancet 390 (2017), S. 2143–2159, PMID 28886907, doi:10.1016/S0140-6736(17)31821-4
Julio Cesar González-Rodríguez et al.: Cervical cancer prevention by vaccination: review. In: Frontiers in Oncology. Band14, 2024, S.1386167, doi:10.3389/fonc.2024.1386167, PMID 38715779 (englisch).
Marc Arbyn et al.: Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. In: Cochrane Database of Systematic Reviews. Band2020, Nr.3, 9. Mai 2018, doi:10.1002/14651858.CD009069.pub3, PMID 29740819, PMC 6494566 (freier Volltext) – (englisch).
Tim Palmer et al.: Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. In: BMJ. Band365, 3. April 2019, S.l1161, doi:10.1136/bmj.l1161, PMID 30944092 (englisch).
Mélanie Drolet et al.: Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. In: Lancet (London, England). Band394, Nr.10197, 10. August 2019, S.497–509, doi:10.1016/S0140-6736(19)30298-3, PMID 31255301.
Jiayao Lei et al.: HPV Vaccination and the Risk of Invasive Cervical Cancer. In: The New England Journal of Medicine. Band383, Nr.14, 1. Oktober 2020, S.1340–1348, doi:10.1056/NEJMoa1917338, PMID 32997908 (englisch).
Milena Falcaro et al.: The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. In: The Lancet. 3. November 2021, doi:10.1016/S0140-6736(21)02178-4, PMID 34741816 (englisch).
Susanne K. Kjaer et al.: Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. In: Journal of the National Cancer Institute. Band113, Nr.10, 1. Oktober 2021, S.1329–1335, doi:10.1093/jnci/djab080, PMID 33876216, PMC 8486335 (freier Volltext) – (englisch).
Tim J. Palmer et al.: Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. In: Journal of the National Cancer Institute. 22. Januar 2024, S.djad263, doi:10.1093/jnci/djad263, PMID 38247547 (englisch).
Marc Arbyn et al.: Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer. In: Journal of the National Cancer Institute. 19. März 2024, S.djae042, doi:10.1093/jnci/djae042, PMID 38501990 (englisch).
Anna R. Giuliano et al.: Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. In: New England Journal of Medicine. Band364, Nr.5, 3. Februar 2011, S.401–411, doi:10.1056/NEJMoa0909537, PMID 21288094, PMC 3495065 (freier Volltext).
Paavonen J et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. In: The Lancet. 369. Jahrgang, Nr.9580, Juni 2007, S.2161–70, doi:10.1016/S0140-6736(07)60946-5, PMID 17602732.
Satoshi Iwata, Kenji Okada, Kei Kawana: Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine. Vaccine 35 (2017), S. 2291–2292, PMID 28325478, doi:10.1016/j.vaccine.2017.03.015, vaccine-kyogikai.umin.jp (PDF; 219 kB)
L. Rambout, L. Hopkins, B. Hutton, D. Fergusson: Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. In: CMAJ. 2007 Aug 28;177(5):469–79. PMID 17671238
Francisco A. R. Garcia, Debbie Saslow: Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention. In: Obstetrics and Gynecology Clinics of North America. Band34, Nr.4, Dezember 2007, S.761–781, ix, doi:10.1016/j.ogc.2007.09.007, PMID 18061868.
Nikolai Madrid Scheller, Björn Pasternak, Henrik Svanström, Anders Hviid: Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. In: JAMA. Band312, Nr.2, Juli 2014, S.187–188, doi:10.1001/jama.2014.2198, PMID 25005658.
David Hawkes: Evidence evolves over time and should be based on data not opinion. In: BMJ Evidence-Based Medicine. Band25, Nr.6, 1. Dezember 2020, S.191–192, doi:10.1136/bmjebm-2019-111222, PMID 31548208.
Marco Torella et al.: Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence. In: Vaccines. Band11, Nr.1, 9. Januar 2023, S.140, doi:10.3390/vaccines11010140, PMID 36679985, PMC 9866915 (freier Volltext) – (englisch).
Ilkka Kalliala et al.: Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial. In: Preventive Medicine. Band146, Mai 2021, S.106473, doi:10.1016/j.ypmed.2021.106473, PMID 33639181 (englisch).
Pola Olczak, Richard B. S. Roden: Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases. In: Vaccines. Band8, Nr.4, 1. Oktober 2020, S.568, doi:10.3390/vaccines8040568, PMID 33019516, PMC 7712070 (freier Volltext) – (englisch).
Emily Farmer et al.: Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer. In: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. Band217, 2021, S.157–195, doi:10.1007/978-3-030-57362-1_8, PMID 33200366, PMC 8564785 (freier Volltext).
Sebastian Kruse et al.: Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. In: OncoImmunology. Band8, Nr.1, 2. Januar 2019, S.e1524694, doi:10.1080/2162402X.2018.1524694, PMID 30546964, PMC 6287800 (freier Volltext).
Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung. In: RKI (Hrsg.): Epidemiologisches Bulletin. Nr.12, 23. März 2007, S.97–106 (rki.de [PDF]).
Über die Zulassung von Gardasil siehe: Zulassung eines neuen Impfstoffes: Gardasil. In: Swissmedic Journal, 6. Jahrgang, Nr. 1, 2007, S. 12–13; swissmedic.ch (PDF; 522 kB).
umin.jp
vaccine-kyogikai.umin.jp
Satoshi Iwata, Kenji Okada, Kei Kawana: Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine. Vaccine 35 (2017), S. 2291–2292, PMID 28325478, doi:10.1016/j.vaccine.2017.03.015, vaccine-kyogikai.umin.jp (PDF; 219 kB)